List of communications

Towards the utilization of cannabinoids as anti-cancer agents in gliomas

David Dávila, Israel López-Valero, Mar Lorente, Sonia Hernández-Tiedra, María Salazar, Sofía Torres, José González, Manuel Guzmán, Aurelio Hernández-Laín, Pilar Sánchez-Gómez, Juan Sepúlveda and Guuillermo Velasco

A large body of evidence shows that cannabinoids, in addition to their well-known palliative effects on some cancer-associated symptoms, can reduce tumour growth in animal models of cancer and specifically of gliomas. The mechanism of cannabinoid anticancer action relies, at least largely, on the ability of these agents to stimulate autophagy-mediated cancer cell death. Moreover, the combined administration of cannabinoids and temozolomide produces a strong anticancer effect, which correlates with an intense activation of the signalling route that triggers the activation of cytotoxic autophagy. Research conducted in our group has also led to the identification of mechanisms of resistance to cannabinoid anticancer action. For example, up-regulation of the growth factor Midlkine (MK) promotes resistance to cannabinoid anticancer action in gliomas via stimulation of the Anaplastic Lymphoma Kinase tyrosine kinase receptor (ALK); and could be a factor of bad prognosis in GBM patients. All these preclinical findings have facilitated the promotion of a clinical study to investigate the safety and efficacy of the combined administration of the cannabis-based medicine Sativex and temozolomide in recurrent GBM.

Format: Oral communication

Organized by